HANSOH PHARMAC. HD-00001 (F:3KY) — Stock Price
HANSOH PHARMAC. HD-00001 (F:3KY) is currently trading at €3.70 EUR, up 0.49% today. Over the past 52 weeks, shares have ranged between €3.10 and €4.76. This page tracks HANSOH PHARMAC. HD-00001's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see 3KY operating cash flow.
HANSOH PHARMAC. HD-00001 (3KY) Stock Price Chart — Daily History & Trading Volume
The chart below tracks HANSOH PHARMAC. HD-00001's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
HANSOH PHARMAC. HD-00001 Income Statement — Revenue, Profit & Earnings by Year
HANSOH PHARMAC. HD-00001's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €15.03 Billion | €12.26 Billion | €10.10 Billion | €9.38 Billion | €9.94 Billion |
| Cost of Revenue | €1.50 Billion | €1.11 Billion | €1.03 Billion | €867.01 Million | €870.04 Million |
| Gross Profit | €13.53 Billion | €11.16 Billion | €9.07 Billion | €8.52 Billion | €9.07 Billion |
| Research & Development | €3.36 Billion | €2.70 Billion | €2.10 Billion | €1.69 Billion | €1.80 Billion |
| SG&A | €4.74 Billion | €4.51 Billion | €4.24 Billion | €4.15 Billion | €4.37 Billion |
| Total Operating Expenses | €9.48 Billion | €8.23 Billion | €7.26 Billion | €6.59 Billion | €6.90 Billion |
| Operating Income | €5.55 Billion | €4.03 Billion | €2.84 Billion | €2.79 Billion | €3.03 Billion |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €3.16 Million | €6.69 Million | €66.68 Million | €58.14 Million | €52.82 Million |
| Income Before Tax | €6.55 Billion | €5.09 Billion | €3.77 Billion | €2.95 Billion | €3.30 Billion |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €5.56 Billion | €4.37 Billion | €3.28 Billion | €2.58 Billion | €2.71 Billion |
HANSOH PHARMAC. HD-00001 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes HANSOH PHARMAC. HD-00001's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €39.90 Billion | €31.66 Billion | €33.04 Billion | €30.00 Billion | €27.16 Billion |
| Total Current Assets | €35.56 Billion | €27.44 Billion | €28.88 Billion | €25.83 Billion | €23.18 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €17.61 Million | €764.71 Million | €2.42 Billion | €4.01 Billion | €4.23 Billion |
| Net Receivables | €3.04 Billion | €3.13 Billion | €3.21 Billion | €3.53 Billion | €3.25 Billion |
| Inventory | €608.92 Million | €651.22 Million | €575.78 Million | €447.89 Million | €410.13 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €4.54 Billion | €2.98 Billion | €7.24 Billion | €7.35 Billion | €7.13 Billion |
| Total Current Liabilities | €4.39 Billion | €2.70 Billion | €6.86 Billion | €2.62 Billion | €3.02 Billion |
| Long-term Debt | — | €0.00 | €39.74 Million | €4.28 Billion | €3.74 Billion |
| Net Debt | — | — | — | €1.62 Billion | — |
| Total Stockholder Equity | €35.36 Billion | €28.68 Billion | €25.79 Billion | €22.65 Billion | €20.03 Billion |
| Retained Earnings | €16.55 Billion | €13.01 Billion | €10.51 Billion | €7.89 Billion | — |
HANSOH PHARMAC. HD-00001 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how HANSOH PHARMAC. HD-00001 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €6.74 Billion | €3.86 Billion | €3.12 Billion | €2.74 Billion | €2.58 Billion |
| Capital Expenditures | €489.46 Million | €524.93 Million | €362.52 Million | €291.82 Million | €475.44 Million |
| Free Cash Flow | €6.25 Billion | €3.34 Billion | €2.75 Billion | €2.45 Billion | €2.10 Billion |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | €2.01 Billion | €1.86 Billion | €652.08 Million | €712.18 Million | €380.87 Million |
| Stock-Based Compensation | €143.27 Million | €137.72 Million | €171.37 Million | €179.42 Million | €65.47 Million |
| Depreciation | €393.02 Million | €401.35 Million | €366.38 Million | €344.60 Million | €278.47 Million |
| Change in Cash | €1.14 Billion | €-3.60 Billion | €3.44 Billion | €-4.01 Billion | €3.73 Billion |
HANSOH PHARMAC. HD-00001 Earnings History — EPS Actual vs. Analyst Estimates
Track HANSOH PHARMAC. HD-00001's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 26, 2026 | — | — | — |
| Mar 19, 2026 | — | — | — |
| Aug 25, 2025 | — | — | — |
| Jun 13, 2025 | — | — | — |
| Mar 21, 2025 | — | — | — |